BrainStorm and Massachusetts General Hospital Sign Definitive Agreement for ALS Clinical Trial

BrainStorm and Massachusetts General Hospital Sign Definitive Agreement for ALS 
Clinical Trial 
NEW YORK, NY and PETACH TIKVAH, ISRAEL -- (Marketwired) -- 03/25/14
--  BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer
of adult stem cell technologies for neurodegenerative diseases,
announced today that it has signed a definitive agreement with the
Massachusetts General Hospital (MGH) in Boston, MA to conduct a Phase
II clinical trial of NurOwn(TM) in amyotrophic lateral sclerosis
(ALS), pending FDA and Institutional Review Board approvals. The
other two clinical sites slated for the multi-center trial are the
University of Massachusetts Memorial (UMass) Hospital and Mayo
Clinic. Dana Farber Cancer Institute's Connell and O'Reilly Cell
Manipulation Core Facility will manufacture the NurOwn cells for MGH
and UMass Hospital. 
"We are excited to be taking the final steps towards FDA approval and
the U.S. trial launch," said Chaim Lebovits, President of BrainStorm.
"It is a privilege to be collaborating with Professor Merit
Cudkowicz, Chair of Neurology at Massachusetts General Hospital,
Professor of Neurology at Harvard Medical School, and leading expert
in the field." 
"It is encouraging that stem cell treatments are now in development
for people with ALS, and we are eager to begin this trial with
BrainStorm's unique approach," commented Merit Cudkowicz, M.D.,
Principal Investigator at MGH. 
About Massachusetts General Hospital
 Massachusetts General Hospital,
founded in 1811, is the original and largest teaching hospital of
Harvard Medical School. The MGH conducts the largest hospital-based
research program in the United States, with an annual research budget
of more than $775 million and major research centers in AIDS,
cardiovascular research, cancer, computational and integrative
biology, cutaneous biology, human genetics, medical imaging,
neurodegenerative disorders, regenerative medicine, reproductive
biology, systems biology, transplantation biology and photomedicine. 
About BrainStorm Cell Therapeutics, Inc.
 BrainStorm Cell
Therapeutics Inc. is a biotechnology company engaged in the
development of first-of-its-kind adult stem cell therapies derived
from autologous bone marrow cells for the treatment of
neurodegenerative diseases. The Company holds the rights to develop
and commercialize its NurOwn technology through an exclusive,
worldwide licensing agreement with Ramot, the technology transfer
company of Tel Aviv University. For more information, visit the
company's website at www.brainstorm-cell.com.  
Safe Harbor Statement
 Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may," "should," "would,"
"could," "will," "expect," "likely," "believe," "plan," "estimate,"
"predict," "potential,"  and similar terms and phrases are intended
to identify these forward-looking statements. The potential risks and
uncertainties include, without limitation, risks associated with
BrainStorm's limited operating history, history of losses; minimal
working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key
executives and on its scientific consultants; ability to obtain
required regulatory approvals; and other factors detailed in
BrainStorm's annual report on Form 10-K and quarterly reports on Form
10-Q available at http://www.sec.gov. These factors should be
considered carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the beliefs,
expectations and opinions of management as of the date of this press
release. We do not assume any obligation to update forward-looking
statements to reflect actual results or assumptions if circumstances
or management's beliefs, expectations or opinions should change,
unless otherwise required by law. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. 
Contacts
BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI)
Mr. Chaim Lebovits, President
Phone: +972-3-9236384
info@brainstorm-cell.com
www.brainstorm-cell.com 
 
 
Press spacebar to pause and continue. Press esc to stop.